AVROBIO, Inc. Files 8-K on Security Holder Vote Matters
Ticker: TECX · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1681087
| Field | Detail |
|---|---|
| Company | Avrobio, Inc. (TECX) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
AVROBIO filed an 8-K for a shareholder vote - details TBD.
AI Summary
On June 11, 2024, AVROBIO, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific details about the matters to be voted on or any associated financial implications.
Why It Matters
This filing indicates that AVROBIO, Inc. is seeking approval from its shareholders on certain corporate actions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information that immediately suggests significant financial or operational risk.
Key Players & Entities
- AVROBIO, Inc. (company) — Registrant
- June 11, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-38537 (legal_document_id) — Commission File Number
FAQ
What specific matters are being submitted for a vote by AVROBIO, Inc.'s security holders?
The filing states that matters are being submitted to a vote of security holders, but it does not specify what those matters are.
When was this 8-K filing submitted?
The filing was submitted on June 11, 2024.
What is AVROBIO, Inc.'s principal executive office address?
The principal executive offices are located at One Broadway, 14th Floor, Cambridge, MA 02142.
What is the Commission File Number for AVROBIO, Inc.?
The Commission File Number is 001-38537.
What is the Standard Industrial Classification code for AVROBIO, Inc.?
The SIC code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,973 words · 8 min read · ~7 pages · Grade level 13.4 · Accepted 2024-06-11 16:29:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AVRO Nasdaq Glo
Filing Documents
- d849908d8k.htm (8-K) — 53KB
- 0001193125-24-159168.txt ( ) — 175KB
- avro-20240611.xsd (EX-101.SCH) — 3KB
- avro-20240611_lab.xml (EX-101.LAB) — 18KB
- avro-20240611_pre.xml (EX-101.PRE) — 11KB
- d849908d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and the exhibits filed or furnished herewith contain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the Merger; the combined company's listing on Nasdaq after the closing of the proposed Merger (the "Closing"); expectations regarding the ownership structure of the combined company; the anticipated timing of the Closing; the expected executive officers and directors of the combined company; expectations regarding the structure, timing and completion of private placement financings, including investment amounts from investors, timing of closing, expected proceeds and impact on ownership structure; each company's and the combined company's expected cash position at the Closing and cash runway of the combined company following the Merger and private financing; the future operations of the combined company, including commercialization activities, timing of launch, buildout of commercial infrastructure; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company,; the location of the combined company's corporate headquarters; anticipated clinical drug development activities and related timelines; and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K and the exhibits filed or furnished herewith are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting AVRO,